How These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics

03:12 EDT 4 Aug 2017 | PR Newswire

NEW YORK, August 4, 2017 /PRNewswire/ --

If you want a Stock Review on AGEN, APTO, RXII, or TENX then come over to and sign up for your free customized report today. On Thursday, August 03, 2017, the NASDAQ Composite and the S&P 500 edged 0.35% and 0.22% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.04%. Five out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, assessed the following Biotechnology equities this morning: Agenus Inc. (NASDAQ: AGEN), Aptose Biosciences Inc. (NASDAQ: APTO), RXi Pharmaceuticals Corp. (NASDAQ: RXII), and Tenax Therapeutics Inc. (NASDAQ: TENX). Learn more about these stocks by registering for free on and accessing the complimentary research reports at:


On Thursday, shares in Lexington, Massachusetts headquartered Agenus Inc. recorded a trading volume of 1.58 million shares. The stock ended at $4.22, rising 2.43% from the last trading session. The Company's shares have gained 5.50% in the last month, 3.43% over the previous three months, and 2.43% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.90% and 2.63%, respectively. Furthermore, shares of Agenus, which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 45.68. See our free and comprehensive research report on AGEN at:

Aptose Biosciences 

Mississauga, Canada headquartered Aptose Biosciences Inc.'s stock finished yesterday's session 3.47% higher at $1.52. A total volume of 292,823 shares was traded. The Company's shares have gained 6.36% in the last month, 17.00% over the previous three months 9.42% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 19.28% and 30.31%, respectively. Furthermore, shares of Aptose Biosciences, which discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada, have an RSI of 59.19. APTO free research report PDF is just a click away at:

RXi Pharma 

At the close of trading on Thursday, shares in Marlborough, Massachusetts headquartered RXi Pharmaceuticals Corp. saw a decline of 3.41%, ending the day at $0.57. The stock recorded a trading volume of 142,581 shares. The stock is trading below its 50-day moving average by 6.65%. Moreover, shares of RXi Pharma, which focuses on developing therapeutics for unmet medical needs, have an RSI of 40.66. Sign up for your complimentary report on RXII at:

Tenax Therapeutics 

Morrisville, North Carolina headquartered Tenax Therapeutics Inc.'s shares ended the day 16.46% lower at $0.37 with a total trading volume of 1.21 million shares, which was above their three months average of 374.70 thousand shares. The Company's shares are trading below their 50-day moving average by 39.03%. Additionally, shares of Tenax Therapeutics, which focuses on the identification, development, and commercialization of a portfolio of products for the critical care market in the US and Canada, have an RSI of 22.52. Register for free on and download the latest research report on TENX at:

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


More From BioPortfolio on "How These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...